{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:07:40Z","timestamp":1791986860233,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12012-024-09933-7","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T13:44:15Z","timestamp":1731159855000},"page":"269-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Meta-analysis of the Risk of Adverse Cardiovascular Events in Patients with Cancer Treated with Inhibitors of the PI3K\/AKT\/mTOR Signaling Pathway"],"prefix":"10.1007","volume":"25","author":[{"given":"Xiao","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongXin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuda","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"1","key":"9933_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano, A., Foo, A. S., Lam, H. Y., Yap, K. C., Jacot, W., Jones, R. H., & Kumar, A. P. (2023). PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer, 22(1), 138.","journal-title":"Molecular Cancer"},{"issue":"10","key":"9933_CR2","doi-asserted-by":"publisher","first-page":"18856","DOI":"10.3390\/ijms151018856","volume":"15","author":"T Li","year":"2014","unstructured":"Li, T., & Wang, G. (2014). Computer-aided targeting of the PI3K\/Akt\/mTOR pathway: Toxicity reduction and therapeutic opportunities. International Journal of Molecular Sciences, 15(10), 18856\u201318891.","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"9933_CR3","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3181\/0904-MR-138","volume":"234","author":"RW Matheny Jr","year":"2009","unstructured":"Matheny, R. W., Jr., & Adamo, M. L. (2009). Current perspectives on Akt Akt-ivation and Akt-ions. Experimental Biology and Medicine, 234(11), 1264\u20131270.","journal-title":"Experimental Biology and Medicine"},{"issue":"11","key":"9933_CR4","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/leu.2016.213","volume":"30","author":"Y Fern\u00e1ndez-Marrero","year":"2016","unstructured":"Fern\u00e1ndez-Marrero, Y., Spinner, S., Kaufmann, T., & Jost, P. J. (2016). Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia, 30(11), 2152\u20132159.","journal-title":"Leukemia"},{"issue":"1","key":"9933_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","volume":"7","author":"W Zhao","year":"2017","unstructured":"Zhao, W., Qiu, Y., & Kong, D. (2017). Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharmaceutica Sinica B, 7(1), 27\u201337.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"33","key":"9933_CR6","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","volume":"29","author":"TW Miller","year":"2011","unstructured":"Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011). Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Journal of Clinical Oncology, 29(33), 4452\u20134461.","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"9933_CR7","doi-asserted-by":"publisher","first-page":"15293","DOI":"10.1007\/s00432-023-05277-x","volume":"149","author":"Z Davoodi-Moghaddam","year":"2023","unstructured":"Davoodi-Moghaddam, Z., Jafari-Raddani, F., Delshad, M., Pourbagheri-Sigaroodi, A., & Bashash, D. (2023). Inhibitors of the PI3K\/AKT\/mTOR pathway in human malignancies; trend of current clinical trials. Journal of Cancer Research and Clinical Oncology, 149(16), 15293\u201315310.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"3","key":"9933_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2174\/156800909788166556","volume":"9","author":"IR Konings","year":"2009","unstructured":"Konings, I. R., Verweij, J., Wiemer, E. A., & Sleijfer, S. (2009). The applicability of mTOR inhibition in solid tumors. Current cancer drug targets, 9(3), 439\u2013450.","journal-title":"Current cancer drug targets"},{"issue":"1","key":"9933_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjh.18736","volume":"202","author":"\u0160pa\u010dek, M., Smolej, L., \u0160imkovi\u010d, M., Nekvindov\u00e1, L., K\u0159\u00edstkov\u00e1, Z., Brychtov\u00e1, Y., \u2026 & Czech CLL Study Group","year":"2023","unstructured":"\u0160pa\u010dek, M., Smolej, L., \u0160imkovi\u010d, M., Nekvindov\u00e1, L., K\u0159\u00edstkov\u00e1, Z., Brychtov\u00e1, Y., \u2026 & Czech CLL Study Group. (2023). Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed\/refractory chronic lymphocytic leukaemia: A real-world analysis from the chronic lymphocytic leukemia patients registry (CLLEAR). British Journal of Haematology, 202(1), 40\u201347.","journal-title":"British Journal of Haematology"},{"key":"9933_CR10","doi-asserted-by":"crossref","unstructured":"Cheung, Y. M. M., Cromwell, G. E., Tolaney, S. M., Min, L., & McDonnell, M. E. (2022). Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.\u00a0Breast cancer research and treatment, 1\u20139.","DOI":"10.1007\/s10549-021-06476-1"},{"issue":"4","key":"9933_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.18553\/jmcp.2019.18259","volume":"25","author":"S Appukkuttan","year":"2019","unstructured":"Appukkuttan, S., Duchesneau, E., Zichlin, M. L., Bhak, R. H., Yaldo, A., Gharibo, M., & Duh, M. S. (2019). A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States. Journal of Managed Care & Specialty Pharmacy, 25(4), 437\u2013446.","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"3","key":"9933_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/jcmm.17665","volume":"27","author":"X Li","year":"2023","unstructured":"Li, X., Ma, X., Miao, Y., Zhang, J., & B., Li, W., \u2026 & Yang, C. (2023). Duvelisib attenuates bleomycin-induced pulmonary fibrosis via inhibiting the PI 3 K\/Akt\/m TOR signalling pathway. Journal of cellular and molecular medicine, 27(3), 422\u2013434.","journal-title":"Journal of cellular and molecular medicine"},{"key":"9933_CR13","doi-asserted-by":"publisher","first-page":"106002802412415","DOI":"10.1177\/10600280241241531","volume":"58","author":"AJ Luboff","year":"2024","unstructured":"Luboff, A. J., & DeRemer, D. L. (2024). Capivasertib: A novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer. Annals of Pharmacotherapy, 58, 10600280241241532.","journal-title":"Annals of Pharmacotherapy"},{"key":"9933_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-024-07324-8","volume":"206","author":"R S\u00e1nchez-Bayona","year":"2024","unstructured":"S\u00e1nchez-Bayona, R., Lopez de Sa, A., Jerez Gilarranz, Y., Sanchez de Torre, A., Alva, M., Echavarria, I., & Martin, M. (2024). Everolimus plus endocrine therapy beyond CDK4\/6 inhibitors progression for HR+\/HER2\u2014advanced breast cancer: A real-world evidence cohort. Breast Cancer Research and Treatment, 206, 1\u20139.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"5","key":"9933_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.euo.2019.06.004","volume":"3","author":"NM Tannir","year":"2020","unstructured":"Tannir, N. M., Msaouel, P., Ross, J. A., Devine, C. E., Chandramohan, A., Gonzalez, G. M. N., & Zurita, A. J. (2020). Temsirolimus versus pazopanib (TemPa) in patients with advanced clear-cell renal cell carcinoma and poor-risk features: A randomized phase II trial. European Urology Oncology, 3(5), 687\u2013694.","journal-title":"European Urology Oncology"},{"issue":"48","key":"9933_CR16","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","volume":"42","author":"C Dolladille","year":"2021","unstructured":"Dolladille, C., Akroun, J., Morice, P. M., Dompmartin, A., Ezine, E., Sassier, M., & Alexandre, J. (2021). Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. European Heart Journal, 42(48), 4964\u20134977.","journal-title":"European Heart Journal"},{"key":"9933_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2023.09.010","volume":"178","author":"WA Zammarrelli III","year":"2023","unstructured":"Zammarrelli, W. A., III., Ma, W., Espino, K., Gordhandas, S., Yeoshoua, E., Ehmann, S., & Makker, V. (2023). Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer. Gynecologic Oncology, 178, 27\u201335.","journal-title":"Gynecologic Oncology"},{"key":"9933_CR18","unstructured":"Madariaga Urrutia, A. Adverse event assessment in research studies involving patients with gynecologic malignancies: Integrating the patient and clinician perspective."},{"key":"9933_CR19","unstructured":"Eldredge, C. (2020).\u00a0Hypersensitivity adverse event reporting in clinical cancer trials: Barriers and potential solutions to studying severe events on a population level\u00a0(Doctoral dissertation, The University of Wisconsin-Milwaukee)."},{"issue":"1","key":"9933_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007). Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine, 26(1), 53\u201377.","journal-title":"Statistics in Medicine"},{"key":"9933_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153644","volume":"227","author":"X Guo","year":"2021","unstructured":"Guo, X., Meng, X., & Liu, R. (2021). Prognostic value of microvessel density in esophageal squamous cell carcinoma-a systematic review and meta-analysis. Pathology-Research and Practice, 227, 153644.","journal-title":"Pathology-Research and Practice"},{"issue":"7","key":"9933_CR22","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s10067-022-06129-8","volume":"41","author":"FF Alberti","year":"2022","unstructured":"Alberti, F. F., Becker, M. W., Blatt, C. R., Ziegelmann, P. K., & da Silva Dal Pizzol, T., & Pilger, D. (2022). Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: An overview with network meta-analysis. Clinical Rheumatology, 41(7), 1965\u20131978.","journal-title":"Clinical Rheumatology"},{"key":"9933_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40271-024-00679-6","volume":"17","author":"LS Brandstetter","year":"2024","unstructured":"Brandstetter, L. S., J\u00edr\u016f-Hillmann, S., St\u00f6rk, S., Heuschmann, P. U., Woeckel, A., & Reese, J. P. (2024). Differences in preferences for drug therapy between patients with metastatic versus early-stage breast cancer: A systematic literature review. The Patient-Patient-Centered Outcomes Research, 17, 1\u201314.","journal-title":"The Patient-Patient-Centered Outcomes Research"},{"issue":"5","key":"9933_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., & Turner, N. C. (2020). Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. Journal of Clinical Oncology, 38(5), 423\u2013433.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"9933_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.annonc.2020.01.074","volume":"31","author":"MP Kolinsky","year":"2020","unstructured":"Kolinsky, M. P., Rescigno, P., Bianchini, D., Zafeiriou, Z., Mehra, N., Mateo, J., & de Bono, J. S. (2020). A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Annals of Oncology, 31(5), 619\u2013625.","journal-title":"Annals of Oncology"},{"issue":"4","key":"9933_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2020","unstructured":"Dreyling, M., Santoro, A., Mollica, L., Lepp\u00e4, S., Follows, G., Lenz, G., & Zinzani, P. L. (2020). Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. American Journal of Hematology, 95(4), 362\u2013371.","journal-title":"American Journal of Hematology"},{"issue":"5","key":"9933_CR27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar, M. J., Capra, M., \u00d6zcan, M., Lv, F., Li, W., Ya\u00f1ez, E., & Zinzani, P. L. (2021). Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 22(5), 678\u2013689.","journal-title":"The Lancet Oncology"},{"key":"9933_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fonc.2017.00330","volume":"7","author":"C Cintas","year":"2018","unstructured":"Cintas, C., & Guillermet-Guibert, J. (2018). Heterogeneity of phosphatidylinositol-3-kinase (PI3K)\/AKT\/mammalian target of rapamycin activation in cancer: Is PI3K isoform specificity important? Frontiers in Oncology, 7, 330.","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"9933_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"SM Maira","year":"2012","unstructured":"Maira, S. M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., & Voliva, C. F. (2012). Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Molecular Cancer Therapeutics, 11(2), 317\u2013328.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"9933_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"C Fritsch","year":"2014","unstructured":"Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., & Sellers, W. R. (2014). Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Molecular Cancer Therapeutics, 13(5), 1117\u20131129.","journal-title":"Molecular Cancer Therapeutics"},{"key":"9933_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0874-7","volume":"13","author":"N Gao","year":"2018","unstructured":"Gao, N., Zhang, T., Ji, J., Xu, K. F., & Tian, X. (2018). The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: Systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 13, 1\u20138.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"4","key":"9933_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.cmet.2013.08.002","volume":"18","author":"DW Lamming","year":"2013","unstructured":"Lamming, D. W., & Sabatini, D. M. (2013). A central role for mTOR in lipid homeostasis. Cell metabolism, 18(4), 465\u2013469.","journal-title":"Cell metabolism"},{"issue":"23","key":"9933_CR33","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., & Moore, L. (2005). Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. Journal of Clinical Oncology, 23(23), 5314\u20135322.","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"9933_CR34","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., & Walsh, D. J. (2005). Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study. Journal of Clinical Oncology, 23(23), 5294\u20135304.","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"9933_CR35","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1002\/cncr.26165","volume":"117","author":"AX Zhu","year":"2011","unstructured":"Zhu, A. X., Abrams, T. A., Miksad, R., Blaszkowsky, L. S., Meyerhardt, J. A., Zheng, H., & Ryan, D. P. (2011). Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma. Cancer, 117(22), 5094\u20135102.","journal-title":"Cancer"},{"issue":"9","key":"9933_CR36","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","volume":"14","author":"DA Rizzieri","year":"2008","unstructured":"Rizzieri, D. A., Feldman, E., Dipersio, J. F., Gabrail, N., Stock, W., Strair, R., & Giles, F. J. (2008). A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 14(9), 2756\u20132762.","journal-title":"Clinical Cancer Research"},{"issue":"9","key":"9933_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/cells11091553","volume":"11","author":"B Walkowski","year":"2022","unstructured":"Walkowski, B., Kleibert, M., Majka, M., & Wojciechowska, M. (2022). Insight into the role of the PI3K\/Akt pathway in ischemic injury and post-infarct left ventricular remodeling in normal and diabetic heart. Cells, 11(9), 1553.","journal-title":"Cells"},{"issue":"1","key":"9933_CR38","doi-asserted-by":"publisher","first-page":"H61","DOI":"10.1152\/ajpheart.00487.2018","volume":"316","author":"W Yang","year":"2019","unstructured":"Yang, W., Wu, Z., Yang, K., Han, Y., Chen, Y., Zhao, W., & W. (2019). BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K\/Akt-mTOR signaling pathway. American Journal of Physiology-Heart and Circulatory Physiology, 316(1), H61\u2013H69.","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"key":"9933_CR39","unstructured":"Lopez-Vaquera, S. (2021). Impact of nicotinamide riboside, a precursor of NAD\u207a on cardiac remodeling after myocardial infarction in rat (Doctoral dissertation, Universit\u00e9 Paris-Saclay)."},{"key":"9933_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.856974","volume":"12","author":"T Saha","year":"2022","unstructured":"Saha, T., & Lukong, K. E. (2022). Breast cancer stem-like cells in drug resistance: A review of mechanisms and novel therapeutic strategies to overcome drug resistance. Frontiers in Oncology, 12, 856974.","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"9933_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.33678\/cor.2022.050","volume":"65","author":"L Askin","year":"2023","unstructured":"Askin, L., & Tanriverdi, O. (2023). Is the microRNA-221\/222 Cluster Ushering in a New Age of cardiovascular diseases. Cor et Vasa, 65(1), 65\u201367.","journal-title":"Cor et Vasa"},{"key":"9933_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.774103","volume":"12","author":"S Mafi","year":"2022","unstructured":"Mafi, S., Mansoori, B., Taeb, S., Sadeghi, H., Abbasi, R., Cho, W. C., & Rostamzadeh, D. (2022). mTOR-mediated regulation of immune responses in cancer and tumor microenvironment. Frontiers in Immunology, 12, 774103.","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"9933_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/08830185.2014.933957","volume":"34","author":"Y Liu","year":"2015","unstructured":"Liu, Y., Zhang, D. T., & Liu, X. G. (2015). mTOR signaling in T cell immunity and autoimmunity. International Reviews of Immunology, 34(1), 50\u201366.","journal-title":"International Reviews of Immunology"},{"issue":"8","key":"9933_CR44","doi-asserted-by":"publisher","first-page":"12353","DOI":"10.1002\/jcp.28042","volume":"234","author":"D Rostamzadeh","year":"2019","unstructured":"Rostamzadeh, D., Yousefi, M., Haghshenas, M. R., Ahmadi, M., Dolati, S., & Babaloo, Z. (2019). mTOR signaling pathway as a master regulator of memory CD8+ T-cells, Th17, and NK cells development and their functional properties. Journal of Cellular Physiology, 234(8), 12353\u201312368.","journal-title":"Journal of Cellular Physiology"},{"issue":"10124","key":"9933_CR45","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet, 391(10124), 933.","journal-title":"The Lancet"},{"issue":"6","key":"9933_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","volume":"72","author":"A Guha","year":"2018","unstructured":"Guha, A., Derbala, M. H., Zhao, Q., Wiczer, T. E., Woyach, J. A., Byrd, J. C., & Addison, D. (2018). Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. Journal of the American College of Cardiology, 72(6), 697\u2013698.","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"9933_CR47","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi, B. B., Reiner, A. S., Kamel, H., Iadecola, C., Okin, P. M., Elkind, M. S., & DeAngelis, L. M. (2017). Risk of arterial thromboembolism in patients with cancer. Journal of the American College of Cardiology, 70(8), 926\u2013938.","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"9933_CR48","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1200\/JOP.18.00149","volume":"14","author":"MK Kirkwood","year":"2018","unstructured":"Kirkwood, M. K., Hanley, A., Bruinooge, S. S., Garrett-Mayer, E., Levit, L. A., Schenkel, C., & Schilsky, R. L. (2018). The state of oncology practice in America, 2018: Results of the ASCO practice census survey. Journal of Oncology Practice, 14(7), e412\u2013e420.","journal-title":"Journal of Oncology Practice"},{"issue":"5","key":"9933_CR49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A. W., King, M. T., & Groves, T. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO extension. JAMA, 319(5), 483\u2013494.","journal-title":"JAMA"},{"issue":"22","key":"9933_CR50","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1161\/CIRCULATIONAHA.118.039180","volume":"139","author":"J Bonsu","year":"2019","unstructured":"Bonsu, J., Charles, L., Guha, A., Awan, F., Woyach, J., Yildiz, V., & Addison, D. (2019). Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation, 139(22), 2594\u20132596.","journal-title":"Circulation"},{"issue":"15","key":"9933_CR51","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi, J. J. (2016). Cardiovascular toxic effects of targeted cancer therapies. New England Journal of Medicine, 375(15), 1457\u20131467.","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"9933_CR52","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/S1470-2045(16)00152-2","volume":"17","author":"B Seruga","year":"2016","unstructured":"Seruga, B., Templeton, A. J., Badillo, F. E. V., Ocana, A., Amir, E., & Tannock, I. F. (2016). Under-reporting of harm in clinical trials. The Lancet Oncology, 17(5), e209\u2013e219.","journal-title":"The Lancet Oncology"},{"key":"9933_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","author":"L Moja","year":"2012","unstructured":"Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D\u2019Amico, R. (2012). Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews. https:\/\/doi.org\/10.1002\/14651858.CD006243.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"35","key":"9933_CR54","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/eurheartj\/ehu282","volume":"35","author":"TF Authors","year":"2014","unstructured":"Authors, T. F., Members, K., & S. D., Knuuti, J., Saraste, A., Anker, S., B\u00f8tker, H. E., \u2026 & Archbold, A. (2014). 2014 ESC\/ESA Guidelines on non-cardiac surgery: Cardiovascular assessment and management\u2014The Joint Task Force on non-cardiac surgery\u2014Cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). European Heart Journal, 35(35), 2383\u20132431.","journal-title":"European Heart Journal"},{"issue":"11","key":"9933_CR55","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2022.4327","volume":"8","author":"A Jfri","year":"2022","unstructured":"Jfri, A., Meltzer, R., Mostaghimi, A., LeBoeuf, N., & Guggina, L. (2022). Incidence of cutaneous adverse events with phosphoinositide 3-kinase inhibitors as adjuvant therapy in patients with cancer: A systematic review and meta-analysis. JAMA Oncology, 8(11), 1635\u20131643.","journal-title":"JAMA Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09933-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-024-09933-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09933-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T04:42:54Z","timestamp":1739162574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-024-09933-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9933"],"URL":"https:\/\/doi.org\/10.1007\/s12012-024-09933-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4675510\/v1","asserted-by":"object"}]},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"2 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}